HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation ...

Kura and Kyowa used the announcement to confirm that they are on track to file a new drug approval application with the FDA ...

The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML ... On the other hand, NPM1 mutation also was noted as a favorable prognostic factor.

Kuro Oncology and partner Kyowa Kirin are on track for an NDA submission for ziftomenib in the second quarter of this year.

Risk categorization of AML based on karyotyping of leukemic blasts has become routine. Mutations in NPM1, CCAAT enhancer-binding protein-α (with double-mutations) and FCT3-internal tandem ...

Syndax Pharma (SNDX) stock rose after Kura Oncology (KURA) posted a mid-stage trial win for a leukemia drug is similar to ...

KOMET-001 trial met its primary endpoint for ziftomenib in R/R NPM1-mutant AML, with statistically significant CR and CRh rates. Kura plans to submit an NDA for ziftomenib in Q2 2025 and initiate ...

The 2024 ELN risk stratification was developed with evidence from an exploratory analysis of pooled data from the phase 3 VIALE-A trial and a phase 1 b study of azacitidine plus venetoclax.